| 6/7/2022 |
LumiraDx (NASDAQ:LMDX) Stock Rating Upgraded by Zacks Investment Research |
etfdailynews.com |
LumiraDx ( NASDAQ:LMDX – Get Rating ) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports.According to Zacks, “LumiraDx Limited is a point of care diagnostics company. Its testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools and workplaces to screen, diagnose, and monitor wellness ... |
| 6/7/2022 |
LumiraDx (NASDAQ:LMDX) Upgraded to “Hold” at Zacks Investment Research |
defenseworld.net |
LumiraDx ( NASDAQ:LMDX – Get Rating ) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks.com reports.According to Zacks, “LumiraDx Limited is a point of care diagnostics company. Its testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools and workplaces to screen, diagnose ... |
| 6/6/2022 |
With 5.2% CAGR, Global Point of Care Diagnostics Market Size Worth USD 51.94 Billion in 2029 |
onenewspage.com |
With 5.2% CAGR, Global Point of Care Diagnostics Market Size Worth USD 51.94 Billion in 2029Published PublishedAccording to Fortune Business Insights, the global Point of Care Diagnostics Market size is projected to reach USD 51.94 billion in 2029, at CAGR of 5.2% during forecast period; Rising Incidence Of Chronic & Infectious Diseases to Propel GrowthPune, India, June 06, 2022 (GLOBE NEWSWIRE) -- The Global point of care diagnostics market ... |
| 6/6/2022 |
Point of Care Diagnostics Market to be Worth $68.59 Billion by 2030: Grand View Research, Inc. |
PR Newswire |
SAN FRANCISCO , June 6, The global point of care diagnostics market size is expected to reach USD 68.59 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.8% from 2022 to 2030. The introduction of advanced technologies such as Telehealth enabled POCT is expected to fuel market growth. Furthermore, the rise in the geriatric population and their ... |
| 6/6/2022 |
Point of Care Diagnostics Market to be Worth $68.59 Billion by 2030: Grand View Research, Inc. |
advfn.com |
SAN FRANCISCO , June 6, 2022 /PRNewswire/ -- The global point of care diagnostics market size is expected to reach USD 68.59 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.8% from 2022 to 2030. The introduction of advanced technologies such as Telehealth enabled POCT is expected to fuel market growth. Furthermore, the rise in the geriatric population ... |
| 6/6/2022 |
With 5.2% CAGR, Global Point of Care Diagnostics Market |
Globe Newswire |
Pune, India, June 06, 2022 (GLOBE NEWSWIRE) -- The Global point of care diagnostics market 2029 is projected to grow during the forecast period due to the increasing incidences of infectious and chronic diseases. Fortune Business Insights‚Ñ¢ publishes this information in a report titled, Point of Care Diagnostics Market 2029 . As per the report, the point of care diagnostics market size was valued at USD 46.65 billion in 2021. The ... |
| 6/2/2022 |
2022-06-02 | NDAQ:LMDX | Press Release | LumiraDx Limited |
stockhouse.com |
... Antibody, SARS-CoV-2 Antigen Pool, SARS-CoV-2 Ag Ultra and Ultra Pool as well as HbA1c, INR, and CRP tests LONDON , June 2, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced it has expanded its cardiovascular offering with a CE Mark for its new NT-proBNP test to aid in the diagnosis of CHF and an updated CE Mark for ... |
| 6/2/2022 |
POC Diagnostics & Testing Market Growth Analysis, Business Demand And Opportunities To 2030 |
express-press-release.net |
Point Of Care Diagnostics & Testing Industry OverviewThe global point of care diagnostics market size was valued at USD 37.03 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.8% from 2022 to 2030.The market is set to gain momentum in the coming years on account of the increase in funding from multiple sources, the rising prevalence of target diseases, and the ... |
| 6/2/2022 |
LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test |
PR Newswire |
... CoV-2 Antibody, SARS-CoV-2 Antigen Pool, SARS-CoV-2 Ag Ultra and Ultra Pool as well as HbA1c, INR, and CRP tests LONDON , June 2, LumiraDx Limited (Nasdaq: LMDX ), a next-generation point of care diagnostics company, today announced it has expanded its cardiovascular offering with a CE Mark for its new NT-proBNP test to aid in the diagnosis of CHF and an updated CE Mark for ... |
| 5/27/2022 |
Research Analysts’ Recent Ratings Updates for LumiraDx (LMDX) - Ticker Report |
Ticker Report |
... LMDX) in the last few weeks:5/25/2022 – LumiraDx was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “LumiraDx Limited is a point of care diagnostics company. Its testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools and workplaces to screen, diagnose, and monitor wellness as well as ... |
| 5/26/2022 |
LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform |
PR Newswire |
... RSV, SARS-CoV-2 Antibody, SARS-CoV-2 Antigen Pool, SARS-CoV-2 Ag Ultra as well as INR, D-Dimer and CRP tests LONDON , May 26, LumiraDx Limited (Nasdaq: LMDX ), a next-generation point of care diagnostics company, today announced its HbA1c test has achieved CE Marking. Used with the LumiraDx Platform, the test provides results in under seven minutes from sample application for the monitoring of individuals with ... |
| 5/26/2022 |
Global Point of Care Diagnostics Market is Expected to |
Globe Newswire |
Newark, NJ, May 26, 2022 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, The global point of care diagnostics market is expected to grow from USD 28.61 billion in 2019 to USD 62.67 billion by 2027, at a CAGR of 10.6% during the forecast period 2020-2027. North America is expected to dominate the market during the forecast period. The awareness and promotional campaigns carried out by the healthcare ... |
| 5/26/2022 |
2022-05-26 | NDAQ:LMDX | Press Release | LumiraDx Limited |
stockhouse.com |
... CoV-2 Antibody, SARS-CoV-2 Antigen Pool, SARS-CoV-2 Ag Ultra as well as INR, D-Dimer and CRP tests LONDON , May 26, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its HbA1c test has achieved CE Marking. Used with the LumiraDx Platform, the test provides results in under seven minutes from sample application for the monitoring of individuals with ... |
| 5/26/2022 |
LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform | Insider Tracking |
insidertracking.com |
PR Newswire LONDON, May 26, 2022 LONDON , May 26, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its HbA1c test has achieved CE Marking. Used with the LumiraDx Platform, the test provides results in under seven minutes from sample application for the monitoring of individuals with diabetes, and as an aid in screening and identifying patients who may be at risk for ... |
| 5/26/2022 |
Global Point of Care Diagnostics Market is Expected to Represent a Value of Over USD 62.67 billion by 2027 : Fior Markets |
Yahoo News |
Fior Market Research LLP Point of Care Diagnostics Market by Platform (Immunoassays, Lateral Flow Assays, Molecular Diagnostics, Microfluidics, And Dipsticks), Product (Glucose Monitoring, Infectious Disease (Hepatitis C, Influenza, Respiratory), Coagulation), Mode, End-User, Region, Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast to 2027Newark, NJ, May 26, 2022 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, The global point of care diagnostics market is expected ... |
| 5/25/2022 |
Worldwide Demand For Point Of Care Test (POCT) Kits Are Projected To Surge At A CAGR Of Around 7% During 2021 To 2028| Fact.MR Forecasts |
latestmarketreports.com |
Shipments of point of care test (POCT) kits are projected to surge at a CAGR of around 7% from 2021 to 2028, as per this new analysis. In 2020, the global point of care diagnostics market stood at US$ 34.1 Bn, and is anticipated to surge to a valuation of US$ 66 Bn by the end of 2028.To remain ‘ahead’ of your competitors, request a sample:https://www.factmr.com ... |
| 5/24/2022 |
Veterinary Diagnostics Market Is Expected To Expand At A CAGR Of 11.2% From 2022 To 2030 |
PRSync |
... of 11.2% from 2022 to 2030.The growth in this market is attributed to factors, such as increased expenditure on animal health, rising incidence of zoonotic diseases & number of veterinary practitioners, technological advancement in point of care diagnostics , and increasing disposable income levels in developing regions. The growing incidence of infectious animal ailments is further poised to augment the demand for veterinary diagnostics. Moreover, advancements in diagnostics together with the ... |
| 5/20/2022 |
2022-05-20 | NDAQ:LMDX | Press Release | LumiraDx Limited |
stockhouse.com |
LMDX 52 minutes ago LONDON , May 20, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, announced today that its rapid COVID-19 antigen assay, LumiraDx SARS-CoV-2 Ag Test has successfully received the Emergency Use Listing (EUL) by the World Health Organization (WHO) in their latest response effort to combat COVID-19.The LumiraDx antigen test is a microfluidic immunofluorescence assay that delivers ... |
| 5/20/2022 |
LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test |
advfn.com |
LONDON , May 20, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, announced today that its rapid COVID-19 antigen assay, LumiraDx SARS-CoV-2 Ag Test has successfully received the Emergency Use Listing (EUL) by the World Health Organization (WHO) in their latest response effort to combat COVID-19.The LumiraDx antigen test is a microfluidic immunofluorescence assay that delivers results for the direct ... |
| 5/20/2022 |
LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test | Insider Tracking |
insidertracking.com |
PR Newswire LONDON, May 20, 2022 LONDON , May 20, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, announced today that its rapid COVID-19 antigen assay, LumiraDx SARS-CoV-2 Ag Test has successfully received the Emergency Use Listing (EUL) by the World Health Organization (WHO) in their latest response effort to combat COVID-19. The LumiraDx antigen test is a microfluidic immunofluorescence assay ... |